ANTHERA PHARMACEUTICALS

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 2004-01-01

Employees: -

Market Cap: -

Website: http://www.anthera.com

Clinical Trials

A Study of Varespladib Infusion in Subjects With Sickle Cell Disease.

Phase 2

Terminated

Conditions: Sickle Cell Disease
Vaso-occlusive Crisis

Interventions: Other: Placebo (Normal Saline)
Drug: Varespladib

First Posted Date: 2012-01-31

Last Posted Date: 2014-03-04

Lead Sponsor: Anthera Pharmaceuticals

Target Recruit Count: 2

Registration Number: NCT01522196

Locations: 🇺🇸
Investigator Site 101, Atlanta, Georgia, United States

CHABLIS-SC1: A Study of the Efficacy and Safety of Subcutaneous Blisibimod in Subjects With Systemic Lupus Erythematosus

Phase 3

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: blisibimod
Drug: Placebo

First Posted Date: 2011-07-18

Last Posted Date: 2017-02-03

Lead Sponsor: Anthera Pharmaceuticals

Target Recruit Count: 442

Registration Number: NCT01395745

Locations: 🇮🇳
Investiagtor Site 513, Mumbai, India
🇹🇭
Investigator Site 204, Muang Chiang Mai, Thailand
🇨🇴
Investigator Site 311, Bogota, Colombia

and more 87 locations

A Study of the Pharmacokinetics and Safety of Varespladib in Subjects With Normal or Impaired Renal Function

Phase 1

Terminated

Conditions: Renal Impairment

Interventions: Drug: varespladib methyl

First Posted Date: 2011-05-25

Last Posted Date: 2012-03-20

Lead Sponsor: Anthera Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT01359579

Locations: 🇺🇸
Investigator Site 101, Orlando, Florida, United States
🇺🇸
Investigator Site 103, Knoxville, Tennessee, United States
🇺🇸
Investigator Site 102, Minneapolis, Minnesota, United States

Study to Assess the Metabolism and Elimination of [14C]-Labeled Varespladib Methyl in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: varespladib methyl

First Posted Date: 2011-05-25

Last Posted Date: 2011-12-20

Lead Sponsor: Anthera Pharmaceuticals

Target Recruit Count: 6

Registration Number: NCT01359605

Locations: 🇺🇸
Celerion, Lincoln, Nebraska, United States

A Trial for Subjects With Systemic Lupus Erythematosus Who Have Completed Protocol AN-SLE3321

Phase 2

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: A-623

First Posted Date: 2011-03-01

Last Posted Date: 2014-02-13

Lead Sponsor: Anthera Pharmaceuticals

Target Recruit Count: 382

Registration Number: NCT01305746

Locations: 🇧🇷
Investigator Site 504, Salvador, Bahia, Brazil
🇧🇷
Investigator Site 510, Sao Paulo, Brazil
🇺🇸
Investigator Site 106, Lake Success, New York, United States

and more 68 locations

PEARL-SC Trial: A Study of the Efficacy, Safety, and Tolerability of A 623 Administration in Subjects With Systemic Lupus Erythematosus

Phase 2

Completed

Conditions: Systemic Lupus Erythematosus

Interventions: Drug: A-623
Other: Placebo Comparator

First Posted Date: 2010-07-15

Last Posted Date: 2014-03-04

Lead Sponsor: Anthera Pharmaceuticals

Target Recruit Count: 547

Registration Number: NCT01162681

Locations: 🇺🇸
Investigator Site 108, Los Angeles, California, United States
🇺🇸
Investigator Site 111, Tulsa, Oklahoma, United States
🇺🇸
Investigator Site 114, Smithtown, New York, United States

and more 71 locations

VISTA-16 Trial: Evaluation of Safety and Efficacy of Short-term A-002 Treatment in Subjects With Acute Coronary Syndrome

Phase 3

Terminated

Conditions: Acute Coronary Syndrome

Interventions: Drug: A-002, varespladib methyl
Drug: Placebo

First Posted Date: 2010-05-25

Last Posted Date: 2012-10-31

Lead Sponsor: Anthera Pharmaceuticals

Target Recruit Count: 5189

Registration Number: NCT01130246

Locations: 🇺🇸
Investigator Site 1018, York, Pennsylvania, United States
🇨🇦
Investigator Site 2020, Lévis, Quebec, Canada
🇺🇸
Investigator Site 1114, Macon, Georgia, United States

and more 358 locations

FRANCIS-ACS Trial: A Study of the Safety and Efficacy of A 002 in Subjects With Acute Coronary Syndromes

Phase 2

Completed

Conditions: Acute Coronary Syndrome

Interventions: Drug: Varespladib Methyl (A-002)

First Posted Date: 2008-08-29

Last Posted Date: 2014-03-04

Lead Sponsor: Anthera Pharmaceuticals

Target Recruit Count: 625

Registration Number: NCT00743925

Locations: 🇬🇪
Cardiological hospital of The Patriarchate of all Georgia, Tbilisi, Georgia
🇬🇪
Cardiological Clinic "Guli", Tbilisi, Georgia
🇺🇦
Department of Cardiology of Central Clinical Hospital, Kharkiv, Ukraine

and more 34 locations

PLASMA 2 Trial: Examination of Once Daily (QD) Dosing of A-002 In Subjects With Stable Coronary Artery Disease

Phase 2

Completed

Conditions: Coronary Artery Disease

First Posted Date: 2007-09-06

Last Posted Date: 2008-01-07

Lead Sponsor: Anthera Pharmaceuticals

Target Recruit Count: 120

Registration Number: NCT00525954

Locations: 🇺🇸
Cardiology PC, Syracuse, New York, United States
🇺🇸
Mobile Heart Specialists, Mobile, Alabama, United States
🇺🇸
Charlotte Cardiovascular Institute, Port Charlotte, Florida, United States

and more 10 locations

Phase III ALTU-135 CP Safety Trial

Phase 3

Terminated

Conditions: Exocrine Pancreatic Insufficiency

Interventions: Drug: Liprotamase

First Posted Date: 2007-07-12

Last Posted Date: 2014-10-24

Lead Sponsor: Anthera Pharmaceuticals

Target Recruit Count: 39

Registration Number: NCT00500084

Locations: 🇺🇸
For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Cincinnati, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy